Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Validation for RZ358
September 2020
SHARING OPTIONS:

REDWOOD CITY, Calif.—The Pediatric Endocrine Society 2020 Annual Meeting, held virtually this year, saw Rezolute Inc. share data regarding its lead clinical asset, RZ358. The company reported that it had validated pharmacokinetic and pharmacodynamic models for RZ358, with Phase 2a data in adult and pediatric patients with congenital hyperinsulinism predicted by said models. RZ358 was found to increase glucose into a normal target range in a disease- and exposure-dependent manner, and Rezolute noted in a press release that its roughly 15-day half-life could enable once- to twice-monthly dosing.
 
“RZ358 is particularly well-suited as a potential treatment for congenital HI in both adults and children … The magnitude and timing of hypoglycemia varies among patients with congenital HI, so a built-in buffer provided by the unique mechanism of action of RZ358 may offer a differentiated way to safely counteract insulin activity, hypoglycemia, and hypoketosis without causing hyperglycemia,” said Dr. Brian Roberts, head of clinical development at Rezolute.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.